Abstract
Rhenium-186(tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in areas of osseous metastases in a manner similar to that of standard bone-scanning agents. It also emits beta particles with sufficient energy to be therapeutically useful. A single intravenous injection of about 33 mCi (1,221 MBq) was given to each of 20 elderly patients with advanced skeletal metastases from hormonally resistant prostate cancer. Prompt, significant relief of pain occurred 80% of the time with no significant side effects and only minimal, transient marrow toxicity. Re-186(Sn) HEDP appears to be a useful new agent for the palliation of painful osseous metastases in prostate cancer.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / radiotherapy
-
Adenocarcinoma / secondary*
-
Adenocarcinoma / therapy
-
Aged
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary*
-
Bone Neoplasms / therapy
-
Estrogens / therapeutic use
-
Etidronic Acid / administration & dosage
-
Etidronic Acid / adverse effects
-
Etidronic Acid / therapeutic use*
-
Humans
-
Male
-
Organometallic Compounds / administration & dosage
-
Organometallic Compounds / adverse effects
-
Organometallic Compounds / therapeutic use*
-
Pain / physiopathology
-
Palliative Care*
-
Prostatic Neoplasms*
-
Quality of Life
-
Radioisotopes
-
Radiotherapy Dosage
-
Rhenium
-
Tin
Substances
-
Estrogens
-
Organometallic Compounds
-
Radioisotopes
-
rhenium-186(tin)etidronate
-
Rhenium
-
Tin
-
Etidronic Acid